Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition
Autore:
Chaturvedi, N; Fuller, JH; Pokras, F; Rottiers, R; Papazoglou, N; Aiello, LP;
Indirizzi:
Univ Coll London, Dept Epidemiol & Publ Hlth, EURODIAB, London, England Univ Coll London London England & Publ Hlth, EURODIAB, London, England Joslin Diabet Ctr, Sect Vasc Cell Biol, Boston, MA 02215 USA Joslin DiabetCtr Boston MA USA 02215 asc Cell Biol, Boston, MA 02215 USA State Univ Ghent, Dept Endocrinol, B-9000 Ghent, Belgium State Univ GhentGhent Belgium B-9000 Endocrinol, B-9000 Ghent, Belgium Agios Pavlos Gen Hosp, Diabet Unit, Salonika, Greece Agios Pavlos Gen Hosp Salonika Greece sp, Diabet Unit, Salonika, Greece
Titolo Testata:
DIABETIC MEDICINE
fascicolo: 4, volume: 18, anno: 2001,
pagine: 288 - 294
SICI:
0742-3071(200104)18:4<288:CPVEGF>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
EURODIAB IDDM COMPLICATIONS; FACTOR VEGF; RETINAL NEOVASCULARIZATION; SERUM LEVELS; RETINOPATHY; PERMEABILITY; CELLS; ADOLESCENTS; EXPRESSION; PLATELETS;
Keywords:
ACE inhibitors; retinopathy; Type 1 diabetes mellitus; VEGF;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Chaturvedi, N St Marys Hosp, Imperial Coll Med, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England St Marys Hosp Norfolk Pl London England W2 1PG 1PG, England
Citazione:
N. Chaturvedi et al., "Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition", DIABET MED, 18(4), 2001, pp. 288-294

Abstract

Aims To determine whether circulating plasma vascular endothelial growth factor (VEGF) is elevated in the presence of diabetic microvascular complications, and whether the impact of angiotensin-converting enzyme (ACE) inhibitors on these complications can be accounted for by changes in circulating VEGF. Methods Samples (299/354 of those with retinal photographs) from the EUCLID placebo-controlled clinical trial of the ACE inhibitor lisinopril in mainly normoalbuminuric non-hypertensive Type 1 diabetic patients were used. Albumin excretion rate (AER) was measured 6 monthly. Geometric mean VEGF levels by baseline retinopathy status, change in retinopathy over 2 years, and by treatment with lisinopril were calculated,Results No significant correlation was observed between VEGF at baseline and age, diabetes duration, glycaemic control, blood pressure, smoking, fibrinogen and von Willebrand factor. Mean VEGF concentration at baseline was 11.5 (95% confidence interval 6.0-27.9) pg/ml in those without retinopathy, 12.9 (6.0-38.9) pg/ml in those with non-proliferative retinopathy, and 16.1(8.1-33.5) pg/ml in those with proliferative retinopathy (P = 0.06 for trend). Baseline VEGF was 15.2 pg/ml in those who progressed by at least one level of retinopathy by 2 years compared to 11.8 pg/ml in those who did not (P = 0.3). VEGF levels were not altered by lisinopril treatment. Results were similar for AER. Conclusions Circulating plasma VEGF concentration is not strongly correlated with risk factor status or microvascular disease in Type 1 diabetes, noris it affected by ACE inhibition. Changes in circulating VEGF cannot account for the beneficial effect of ACE inhibition on retinopathy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 09:27:21